WEKO3
アイテム
Surgical therapy for breast cancer liver metastases
http://hdl.handle.net/10295/00005749
http://hdl.handle.net/10295/000057493fc2ce01-8859-422a-8105-d73388eb14b6
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
iA_2021_27 (255.7 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-08-10 | |||||
| タイトル | ||||||
| タイトル | Surgical therapy for breast cancer liver metastases | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 主題 | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Breast cancer | |||||
| 主題 | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | liver metastases | |||||
| 主題 | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | surgical resection | |||||
| 主題 | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | radiofrequency ablation (RFA) | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 作成者 |
Terata, Kaori
× Terata, Kaori× Imai, Kazuhiro× Wakita, Akiyuki× Sato, Yusuke× Motoyama, Satoru× Minamiya, Yoshihiro |
|||||
| 内容記述 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Breast cancer is the most commonly diagnosed cancer in females worldwide. If diagnosed early, patients generally have good outcomes. However, approximately 20% to 30% of all women diagnosed with breast cancer develop metastatic disease. Metastatic breast cancer is incurable, but there is growing evidence that resection or other local therapy for breast cancer liver metastases (BCLM) may improve survival. We aimed to review indications for and outcomes of perioperative liver resection and other local therapies for BCLM. In this series, we reviewed 11 articles (605 patients) focusing on surgical resection and 7 articles (266 patients) describing radiofrequency ablation (RFA) for BCLM. Median disease-free survival (DFS) after surgical resection was 23 months (range, 14–29 months) and median overall survival (OS) was 39.5 months (range, 26–82 months). One, 3- and 5-year survivals were 89.5%, 70%, and 38%, respectively. The factors favoring better outcomes are hormone receptor positive primary breast cancer status, R0 resection, no extrahepatic metastases (EHM), small BCLM, and solitary liver metastases. On the other hand, the median DFS with RFA was 11 months, median OS was 32 months, and the 3- and 5-year OS were 43% and 27%, respectively. The clinical features that are indications for RFA are smaller tumor and higher EHM rate than those favoring surgical resection (2.4 vs. 4.0 cm and 46% vs. 27%). The merits of RFA are its high technical success rate, low morbidity, short hospital stay, and that it can be repeated. Although results are as yet limited, in carefully selected patients, resection or other local therapies such as RFA, render BCLM potentially provide prognostic improvement. | |||||
| 言語 | en | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 書誌情報 |
en : Translational Cancer Research 巻 9, 号 8, p. 5053-5062, 発行日 2020 |
|||||
| 収録物識別子 | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 2219-6803 | |||||
| 出版者 | ||||||
| 出版者 | Translational Cancer Research | |||||
| 言語 | en | |||||
| 関連情報 | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.21037/tcr-20-1598 | |||||
| 権利情報 | ||||||
| 言語 | en | |||||
| 権利情報 | © Translational Cancer Research. All rights reserved. | |||||
